The increase in meningioma risk in users of COC containing NOMAC is limited 72 in women aged 20-34 years, even after long periods of use. Because age is the most important risk factor, a maximum of five years of E2/NOMAC combination use in women aged 35-44 and 30 74 months of use in women aged 45-54 years might be considered reasonable thresholds. Considering 75 these thresholds, we can expect respectively one case of meningiomas out of respectively 992 and 76 1923 treated cases.
Nomegestrol acetate for symptomatic endometriosis and meningioma risk: understandable statistics for true shared decision-making / P. Vercellini, G. Esposito, C. Santucci, F. Parazzini, C. La Vecchia. - In: EUROPEAN JOURNAL OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE BIOLOGY. - ISSN 0301-2115. - (2023), pp. 1-6. [Epub ahead of print] [10.1016/j.ejogrb.2023.05.002]
Nomegestrol acetate for symptomatic endometriosis and meningioma risk: understandable statistics for true shared decision-making
P. VercelliniPrimo
;G. Esposito
Secondo
;C. Santucci;F. ParazziniPenultimo
;C. La VecchiaUltimo
2023
Abstract
The increase in meningioma risk in users of COC containing NOMAC is limited 72 in women aged 20-34 years, even after long periods of use. Because age is the most important risk factor, a maximum of five years of E2/NOMAC combination use in women aged 35-44 and 30 74 months of use in women aged 45-54 years might be considered reasonable thresholds. Considering 75 these thresholds, we can expect respectively one case of meningiomas out of respectively 992 and 76 1923 treated cases.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Nomegestrol short comm_Vercellini.pdf
embargo fino al 04/05/2024
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
359.27 kB
Formato
Adobe PDF
|
359.27 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
